Portfolio & Ventures
Partnering with the Innovators Shaping Healthcare's Future
Waypoint Biomedical Holdings serves as a launch platform for emerging biomedical companies. We identify high-potential ventures, provide strategic support, and align them with capital and market pathways for long-term growth.
Current Phase
Actively Seeking Portfolio Companies
As of 2026, Waypoint Biomedical Holdings is in its active growth phase — identifying and evaluating early-stage biomedical companies for partnership, investment, and portfolio inclusion. We welcome introductions from founders, advisors, and intermediaries.
Investment Focus
Sectors We Target
Our investment focus is rooted in our founding expertise in diagnostics and expanded to encompass the full spectrum of biomedical innovation.
Diagnostics & Point-of-Care
Rapid diagnostic technologies for clinical, consumer, and field applications — building on our founding expertise in disposable rapid tests.
Healthcare Technology
Digital health platforms, monitoring solutions, and connected devices that improve patient outcomes and clinical workflows.
Defense & Security Applications
Biomedical technologies with dual-use potential in homeland security, defense, and public safety — a core area since our founding.
Adjacent Life Sciences
Complementary sectors including medical devices, laboratory tools, and biotech platforms that align with our long-term growth philosophy.
What We Look For
Partnership Criteria
We evaluate potential portfolio companies across five key dimensions to ensure alignment with our long-term investment philosophy.
Stage
Early-stage & pre-public
Companies preparing for public market entry or strategic acquisition
Technology
Differentiated & defensible
Proprietary technology with clear IP and competitive moat
Market
Real-world healthcare impact
Addressable markets with demonstrated clinical or commercial need
Team
Execution-ready leadership
Management teams capable of scaling operations and attracting capital
Path
Clear exit or growth runway
Defined pathway to public markets, acquisition, or institutional investment
Think You're a Fit?
We welcome introductions from founders, advisors, and intermediaries with early-stage biomedical opportunities.
Our Roots
Founding Innovation Legacy
Waypoint Biomedical was founded in 2004 with a focus on disposable rapid diagnostic tests. These original products established the company's expertise in consumer and point-of-care diagnostics — a foundation that informs our investment thesis today.
Drink Detective
A rapid test designed to detect date-rape drugs including GHB and Ketamine in beverages — an early example of consumer-facing biomedical innovation.
Drugs of Abuse Panel
Rapid screening tests for cocaine, marijuana, and other substances — developed for OTC self-testing and point-of-care clinical settings.
Homeland Security Tests
Rapid field detection technologies developed for homeland security and defense applications, demonstrating the breadth of our early diagnostic platform.
Note: The products listed above represent Waypoint Biomedical's historical innovation from its founding period (2004–2009). The company is currently in its restructuring and growth phase, actively seeking new portfolio companies and partnerships aligned with its renewed vision.
Introduce Your Company to Waypoint
If you represent an early-stage biomedical company or know one that could benefit from our platform, capital, and strategic network — we'd like to hear from you.